Vertex Acquires Tectonic Therapeutic for $3.50/share + CVR

TL;DR

Vertex just bought Tectonic for $3.50 cash + CVR per share, boosting their gene editing game.

AI Summary

Tectonic Therapeutic, Inc. announced on June 20, 2024, the completion of its acquisition by a subsidiary of Vertex Pharmaceuticals Incorporated. The transaction was previously announced on April 22, 2024, and involved the acquisition of all outstanding shares of Tectonic Therapeutic for $3.50 per share in cash, plus one non-tradable contingent value right per share. This acquisition is expected to advance Vertex's efforts in cystic fibrosis and other serious diseases.

Why It Matters

This acquisition allows Vertex Pharmaceuticals to integrate Tectonic's novel gene editing technologies, potentially accelerating the development of new therapies for serious diseases like cystic fibrosis.

Risk Assessment

Risk Level: medium — The acquisition is complete, but the value of the contingent value right (CVR) is uncertain and depends on future development milestones.

Key Numbers

• $3.50 — Cash per share (The cash amount paid to Tectonic shareholders at closing.)
• 1 — Contingent Value Right (CVR) per share (An additional right for shareholders tied to future development milestones.)

Key Players & Entities

• Tectonic Therapeutic, Inc. (company) — Acquired company
• Vertex Pharmaceuticals Incorporated (company) — Acquiring company
• $3.50 (dollar_amount) — Cash consideration per share
• June 20, 2024 (date) — Closing date of acquisition
• April 22, 2024 (date) — Date of initial acquisition announcement

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TECX Nasdaq Glo

Filing Documents

• d852858d8k.htm (8-K) — 160KB
• d852858dex31.htm (EX-3.1) — 6KB
• d852858dex32.htm (EX-3.2) — 6KB
• d852858dex33.htm (EX-3.3) — 4KB
• d852858dex101.htm (EX-10.1) — 109KB
• d852858dex102.htm (EX-10.2) — 58KB
• d852858dex103.htm (EX-10.3) — 242KB
• d852858dex104.htm (EX-10.4) — 50KB
• d852858dex106.htm (EX-10.6) — 160KB
• d852858dex107.htm (EX-10.7) — 72KB
• d852858dex108.htm (EX-10.8) — 71KB
• d852858dex161.htm (EX-16.1) — 2KB
• d852858dex991.htm (EX-99.1) — 17KB
• d852858dex992.htm (EX-99.2) — 148KB
• d852858dex993.htm (EX-99.3) — 307KB
• d852858dex994.htm (EX-99.4) — 260KB
• 0001193125-24-164480.txt ( ) — 2173KB
• tecx-20240620.xsd (EX-101.SCH) — 3KB
• tecx-20240620_def.xml (EX-101.DEF) — 14KB
• tecx-20240620_lab.xml (EX-101.LAB) — 23KB
• tecx-20240620_pre.xml (EX-101.PRE) — 15KB
• d852858d8k_htm.xml (XML) — 6KB

Risk Factors

Risk Factors The information set forth in the section of the Proxy Statement/Prospectus entitled " Risk Factors " beginning on page 36 is incorporated herein by reference. Financial Information The information set forth in Item 9.01 of this Current Report on Form 8-K concerning the financial information of Tectonic and AVROBIO is incorporated herein by reference. The unaudited pro forma condensed combined financial information of Tectonic and AVROBIO as of and for year ended December 31, 2023 and for the three months ended March 31, 2024 is set forth in Exhibit 99.4 hereto and is incorporated herein by reference. II-4

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations Management's Discussion and Analysis of Financial Condition and Results of Operations of AVROBIO and Tectonic, respectively, for the years ended December 31, 2023 and 2022 is set forth in the section of the Proxy Statement/Prospectus entitled " AVROBIO's Management's Discussion and Analysis of Financial Condition and Results of Operations " and " Tectonic Management's Discussion and Analysis of Financial Condition and Results of Operations " beginning on pages 397 and 410, respectively, and is incorporated herein by reference. Management's Discussion and Analysis of Financial Condition and Results of Operations for AVROBIO for the quarter ended March 31, 2024 is included in AVROBIO's quarterly report on Form 10-Q for the quarter ended March 31, 2024 that was filed with the SEC on May 9, 2024, and is incorporated herein by reference. Management's Discussion and Analysis of Financial Condition and Results of Operations for Tectonic for the quarter ended March 31, 2024 is set forth in Exhibit 99.2 to this Current Report on Form 8-K, and is incorporated herein by reference.

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management The following table sets forth certain information regarding beneficial ownership of the Company's common stock as of June 20, 2024 and reflects the 1-for-12 reverse stock split of the Company's common stock effected June 20, 2024 (the "Reverse Stock Split"). Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power with respect to the securities as well as any shares of common stock that the individual or entity has the right to acquire within 60 days of June 20, 2024 the exercise of stock options or other rights. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Except as noted by footnote, and subject to community property laws where applicable, the Company believes, based on the information provided to them, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them. The table lists applicable percentage ownership based on 14,734,323 shares of common stock outstanding as of June 20, 2024. The number of shares beneficially owned includes shares of common stock that each person has the right to acquire within 60 days, including upon the exercise of stock options and the vesting of restricted stock units. These stock options and restricted stock units shall be deemed to be outstanding for the purpose of computing the percentage of outstanding shares of the Company's common stock expected to be owned by such person but shall not

View Full Filing

View this 8-K filing on SEC EDGAR